Oppenheimer analyst Jay Olson maintains $Enanta Pharmaceuticals (ENTA.US)$ with a hold rating, and adjusts the target price from $16 to $14.
According to TipRanks data, the analyst has a success rate of 37.6% and a total average return of 10.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Enanta Pharmaceuticals (ENTA.US)$'s main analysts recently are as follows:
Enanta reported Q4 results highlighting quarterly HCV royalties of $14.6M, operating expenses of $44.5M, and cash reserves of $248.2M, anticipated to sustain operations into 2027. The company is poised to announce topline results from its Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
The firm noted that the Q4 report was straightforward and emphasized the critical nature of the upcoming RSVPEDs readout in December, which is expected to be a key determinant of zelicapavir's future potential in RSV.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Jay Olson維持$Enanta Pharmaceuticals (ENTA.US)$持有評級，並將目標價從16美元下調至14美元。
根據TipRanks數據顯示，該分析師近一年總勝率為37.6%，總平均回報率為10.8%。
此外，綜合報道，$Enanta Pharmaceuticals (ENTA.US)$近期主要分析師觀點如下：
Enanta報告了第四季度的業績，強調了1460萬美元的季度HCV版稅，4450萬美元的營業費用，以及24820萬美元的現金儲備，預計能支持公司運營至2027年。該公司準備在12月公佈其RSV嬰兒和兒童中Zelicapavir第二階段RSVPEDs研究的上線結果。
公司指出第四季度報告直截了當，並強調了在12月即將公佈的RSVPEDs結果的關鍵性質，該結果預計將成爲Zelicapavir在RSV領域未來潛力的關鍵決定因素。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
